Press releases
7 May 2020, Zwingenberg

Change in the Management Board of BRAIN AG

Chief Financial Officer Manfred Bender is leaving the biotechnology company at the end of the current financial year. Lukas Linnig to become the new CFO.

The biotechnology company B.R.A.I.N. Biotechnology Research and Information Network AG announces that Chief Financial Officer Manfred Bender will leave the company at his own request on 30 September 2020. Mr Bender will take on a new assignment and has therefore asked the Supervisory Board to terminate his contract prematurely. The Supervisory Board has complied with this request.

The new Chief Financial Officer will be Lukas Linnig, the current Head of Finance, Controlling and Legal. Linnig has worked for the company since April 2017 and he previously advised BRAIN as a consultant during the IPO.

Dr Georg Kellinghusen, Chairman of the Supervisory Board, says: “We regret Mr Bender's decision, but we respect it. We thank him for his great contribution and commitment to BRAIN AG. With Lukas Linnig, we have found a successor who knows the company extremely well. There is sufficient time for an orderly transition until Mr Bender leaves the company.”

Adriaan Moelker, CEO BRAIN AG, commented: “Lukas Linnig has proven that he has all the skills for a strong CFO. I am very pleased to have him on the management board and I am confident that with Lukas’ appointment we are taking an important step in building a strong future-orientated team.”

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe’s leading technology companies in the field of industrial biotechnology, the core discipline of the bioeconomy. As such, BRAIN identifies previously untapped efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by means of “Nature’s Toolbox” are successfully applied in the chemicals, cosmetics and food industries. BRAIN's business model is based on two pillars. The BioScience segment mainly comprises research and development business with industrial partners, and the company’s own research and development. The BioIndustrial segment consists mainly of business with industrially scalable products. As part of a growth-oriented industrialization strategy, BRAIN AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since February 2016 as the first company in the bioeconomy. Further information is available at www.brain-biotech.com.

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.

Share this page